Salute e Benessere

Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in…

ForTec has initiated procedures in select territories with the 6 Saphira towers that it currently has in the field, and an expanded rollout of the program throughout the U.S. is anticipated to commence in the third quarter of 2024 with 12 additional Saphira towers that ForTec is preparing for deployment. ForTec has initiated procedures in select territories with the 6 Saphira towers that it currently has in the field, and an expanded rollout of the program throughout the U.S. is anticipated…

UNION therapeutics announces successful completion of the ADESOS Phase 2b study…

Presentation details Presentation details Presentation: Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a Phase2brandomized, double-blind, placebo-controlled clinical trial (ADESOS) Presenter: Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at TheGeorge Washington University School of Medicineand Health Sciences and Signatory Investigator for ADESOS Date and time: Monday June 10, 2024, at...

Global Heart Hub urges people to "Think Cardiomyopathy" with new Global Campaign

Think Cardiomyopathy Think Cardiomyopathy Led by GHH's Cardiomyopathy Patient Council which has 24 patient organisation affiliates across 15 countries, this year's campaign focuses on patient and advocate stories on the impact of cardiomyopathy and the importance of recognising symptoms and knowing your family history. "Cardiomyopathy is too often underdiagnosed, misdiagnosed or diagnosed too late. It is the predominant cause of sudden cardiac death in people under 35. We want to raise...

Nyxoah to Participate in the Jefferies Global Healthcare Conference

Nyxoah to Participate in the Jefferies Global Healthcare ConferenceMont-Saint-Guibert, Belgium – June 3, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies Global Healthcare Conference, which takes place June 5 – 6, 2024 in New York...

Information on the total number of voting rights and shares

REGULATED INFORMATIONInformation on the total number of voting rights and sharesMont-Saint-Guibert (Belgium), June 3, 2024, 10:15 pm CET / 4:15 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 5,902,793.43 Total number of securities carrying voting rights: 34,360,390 (all ordinary...

Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve…

ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3Sarclisa, in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd reduced the risk of recurrence or death by 40% versus VRd followed by Rd in the investigational use for transplant-ineligible newly diagnosed multiple myeloma patientsKey primary endpoint of...

Publication relating to transparency notifications

REGULATED INFORMATIONPublication relating to transparency notificationsMont-Saint-Guibert (Belgium), June 3, 2024, 10.05pm CET / 4.05pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received four transparency notifications as detailed below.FMR LLCOn May 30, 2024, Nyxoah received a transparency notification from FMR LLC following the crossing above the 3%...

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment...

Biesterfeld Group acquires Aerontec and expands its presence in Africa

Dirk J. Biesterfeld, Chairman of the Supervisory Board of Biesterfeld AG, explains: "The sub-Saharan region is of high interest for Biesterfeld. With this acquisition, we are not only pursuing our global growth strategy but have also gained a great team, which shares the same goals and values that we hold at Biesterfeld. I welcome Graham Blyth and all new colleagues as part of our Biesterfeld family. We are looking forward to a successful future together." Dirk J. Biesterfeld, Chairman…

HistoIndex to Showcase Groundbreaking AI-powered Stain-free Digital Pathology…

Accepted as a late-breaker, the oral presentation by Dr. Jörn M Schattenberg, Professor of Medicine and Director of the Department of Medicine II at the University Medical Center Homburg and the University of the Saarland Germany, compares the specific fibrotic features identified by qFibrosis with ordinal scoring and NITs in their correlation to fibrosis progression. Commenting on the significance of this work, Dr. Schattenberg stated, "There is a need to improve the methods we are…

Evosep Unveils Groundbreaking Innovations in Scalable Proteomics Workflows at…

Fully Automated Workflows: Capable of processing over 500 plasma samples per day, these workflows are designed to maximize efficiency and throughput while minimizing manual labor and potential for error, particularly benefiting drug discovery and translational research. Fully Automated Workflows:Capable of processing over 500 plasma samples per day, these workflows are designed to maximize efficiency and throughput while minimizing manual labor and potential for error, particularly...

BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA…

CelluTx's Chief Executive Officer, Maurits Geerlings said, "We are very pleased to engage with BioCina for the worldwide deployment of the RBPS minicircle DNA technology. BioCina has proven capabilities and the highest commitment to its customers, which has been fundamental to our partnering with BioCina." CelluTx's Chief Executive Officer,Maurits Geerlingssaid, "We are very pleased to engage with BioCina for the worldwide deployment of the RBPS minicircle DNA technology. BioCina…

Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet…

Saint-Herblain (France), June 3, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical trials of Lyme disease vaccine candidate, VLA15, were published in the peer-reviewed medical journal,The Lancet Infectious Diseases. These trials, as well as a third Phase 2 trial in pediatric participants, supported the design of the current pivotal Phase 3 trial, 'Vaccine Against Lyme for Outdoor Recreationists'...

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 3 June 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the…

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer…

VANCOUVER, BC, June 3, 2024 /PRNewswire/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by focusing on earlier detection. According to Johns Hopkins Medicine, up to 80% of patients are diagnosed at advanced stages, which are significantly harder to treat. A new study published in the journal Cell Genomics demonstrates that researchers have identified key protein biomarkers for early detection of…

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 3, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from May 27, 2024 to May 31, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...

BioPharmaSpec Announces Major Investments in Mass Spectrometry and Related…

The state-of-the-art instrumentation will support and accelerate BioPharmaSpec's clients' efforts in successful biologics product development BioPharmaSpec ”), the leading global Contract Research Organization (CRO) for discovery and preclinical characterization of biopharmaceuticals, has made major new investments in instrumentation, including top-of-the-range Mass Spectrometers, to support its clients in their product development goals. On June 1st, 2024, BioPharmaSpec announced that it...

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging…

Media Release COPENHAGEN, Denmark; June 3, 2024 Results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate in patients with recurrent or metastatic HNSCC, presented in a rapid oral session at 2024 ASCO® Annual MeetingHNSCC is the sixth most common cancer worldwide, with incidence rates expected to increase 30% by 2030iGenmab A/S(Nasdaq:GMAB)announced today that data from the Phase 2 innovaTV 207 trial ( NCT03485209 )...

Waters Sets New Standards for High Resolution Performance and Speed with Xevo…

"Understanding complex diseases requires analysis of thousands of samples from large human cohorts to provide statistically valid studies. This puts increased pressure on drug discovery scientists to deliver high-quality data in shorter run times," said Dr. Udit Batra, CEO and President of Waters Corporation. "The Xevo MRT mass spectrometer is a next generation QTof built from the ground up to address this unmet need, delivering high resolution and speed without compromising…

Zero Candida Announces its Intent to Complete Listing of its Shares on the TSX…

ZC is a private FemTech technology company incorporated under the corporate laws of the State of Israel. ZC is developing an AI smart tampon-like device based on AI on a therapeutic light source with a selected wave-length and intensity that can treat the Candida fungus with successfully of 99.999% an POC. Vulvo-Vaginal Candidiasis ("VVC") affects about 75% of women globally, each year 138 million women are affected world-wide and 492 million over their lifetime. Recurrent VVC (4 or…

Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial…

Evaxion's AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melanoma patientsFindings further confirm and validate the precision and predictive power of Evaxion's AI vaccine target discovery and design platform, AI-Immunology™ COPENHAGEN, Denmark, June03, 2024(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...

MGI Tech Shares New Data on Core DNEBSEQ Technology and Showcases Latest…

Additionally, Dr. Marie-Laure Yaspo from Germany's ALACRIS Theranostics shared insights into the quality upgrade made possible by the new StandardMPS 2.0 (SM 2.0) sequencing chemistry, first announced during AGBT 2024 in February. Enabled by updated sequencing reagents and software, SM 2.0 delivers an impressive proportion of ≥85% for base quality scores reaching or exceeding Q40 during sequencing on MGI's DNBSEQTM platform. Continuous improvement of the sequencing chemistry, without…

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation…

~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington's disease ~~ Receiving RMAT designation enables increased collaboration with the FDA on regulatory approval planning, in addition to the opportunity for expedited product development ~ LEXINGTON, Mass. and AMSTERDAM, June03, 2024(GLOBE NEWSWIRE) --uniQureN.V. (NASDAQ: QURE), a leading...

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved…

— Vibrance-1 Phase 2 Study of ALKS 2680 in Patients With Narcolepsy Type 1 Is Ongoing — — Vibrance-1 Phase 2 Study of ALKS 2680 in Patients With Narcolepsy Type 1 Is Ongoing — DUBLIN,June 3, 2024/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily...

Altri Comunicati